A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

Sagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer. Women with ovarian cancer recurring within 6 months of end of last pl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2011-11, Vol.22 (11), p.2411-2416
Hauptverfasser:	Rustin, G., Reed, N., Jayson, G.C., Ledermann, J.A., Adams, M., Perren, T., Poole, C., Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M., Kaye, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Benzothiazoles - administration & dosage Benzothiazoles - adverse effects Biological and medical sciences Disease-Free Survival Drug Administration Schedule Drug Resistance, Neoplasm epothilone Epothilones - administration & dosage Epothilones - adverse effects Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Infusions, Intravenous Medical sciences Middle Aged ovarian cancer Ovarian Neoplasms - drug therapy Pharmacology. Drug treatments phase II sagopilone Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!